Seres Therapeutics (MCRB) Misses Q3 EPS by 6c

Seres Therapeutics Reports Third Quarter 2015 Financial Results and Provides Business Update

FDA granted Orphan Drug Designation for SER-109 in recurrent C. difficile infection (CDI)

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics Inc. (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today reported financial results and provided a business update for the third quarter ended September 30, 2015.

Over the past few months, we have continued to make significant progress in the microbiome space by advancing our promising pipeline of Ecobiotic® therapeutics, said Roger Pomerantz, M.D., President, CEO and Chairman of Seres. We received Orphan Drug Designation for SER-109, our first-in-field treatment... More

Seres Therapeutics Appoints Kurt Graves to Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics Inc. (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today announced the appointment of Kurt Graves to the companys board of directors. Mr. Graves, the Chairman, President and CEO of Intarcia Therapeutics, is an industry leader who brings to Seres extensive experience from his 25-year career at top-tier pharmaceutical and biotech companies. He has developed and launched major brands in multiple disease areas and successfully built and managed several of the industrys largest franchises.

Kurt has played a key role leading efforts to deliver significant... More